Medical technology company AngioDynamics Inc. (ANGO) continues to advance its portfolio of devices designed for vascular, oncology, and surgical applications. With multiple clinical trials underway, recent study results published in leading journals, and updated financial guidance, the company is drawing attention as it navigates a pivotal period in its growth trajectory.
Expanding Clinical Evidence
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com